Aspirin Research Today is a free monthly online journal that collates and summarizes the latest research about Aspirin, including details on acetylsalicylic acid, baby aspirin, side effects, overdose, allergy.

Aspirin response and failure in diabetic patients with cardiovascular disease.

Yan Y, Phillips DR

Portola Pharmaceuticals Inc, 270 E. Grand Avenue, Suite 22, South San Francisco, California 94080, USA.

Platelets are known to play a pivotal role not only in the formation of arterial thrombosis but also in the progression of atherosclerotic disease. Recent data suggest that these activities of platelets have become enhanced in patients with type 2 diabetes, accounting for many of the cardiovascular complications. Although aspirin is the most commonly used drug to regulate platelet function, many patients do not receive the expected clinical benefit of this drug and do not have the expected inhibition of platelet function, perhaps because of platelet hyperactivity in diabetes. The data suggest that aspirin might be a less than adequate antithrombotic for type 2 diabetes and that alternative therapies (e.g. combinations with clopidogrel or new antithrombotic therapies) are required to effectively manage the prevalent thrombotic complications associated with this disease.

Published 22 March 2005 in Curr Opin Pharmacol, 5(2): 190-7.
Full-text of this article is available online (may require subscription).

© 2004-2008 Aspirin Research Today. All Rights Reserved.